191 related articles for article (PubMed ID: 38539478)
1. Decrease in Heparan Sulphate Binding in Tropism-Retargeted Oncolytic Herpes Simplex Virus (ReHV) Delays Blood Clearance and Improves Systemic Anticancer Efficacy.
Vannini A; Parenti F; Forghieri C; Vannini G; Barboni C; Zaghini A; Gianni T; Campadelli-Fiume G
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539478
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Naïve and HSV-Preimmune Mice.
Vannini A; Parenti F; Barboni C; Forghieri C; Leoni V; Sanapo M; Bressanin D; Zaghini A; Campadelli-Fiume G; Gianni T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627072
[TBL] [Abstract][Full Text] [Related]
3. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
4. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.
Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line.
Vannini A; Leoni V; Sanapo M; Gianni T; Giordani G; Gatta V; Barboni C; Zaghini A; Campadelli-Fiume G
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445744
[TBL] [Abstract][Full Text] [Related]
7. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.
Leoni V; Vannini A; Gatta V; Rambaldi J; Sanapo M; Barboni C; Zaghini A; Nanni P; Lollini PL; Casiraghi C; Campadelli-Fiume G
PLoS Pathog; 2018 Aug; 14(8):e1007209. PubMed ID: 30080893
[TBL] [Abstract][Full Text] [Related]
8. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
9. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors.
Ingusci S; Hall BL; Cohen JB; Glorioso JC
Mol Ther Oncol; 2024 Mar; 32(1):200761. PubMed ID: 38596286
[TBL] [Abstract][Full Text] [Related]
11. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
12. Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.
Leoni V; Gatta V; Palladini A; Nicoletti G; Ranieri D; Dall'Ora M; Grosso V; Rossi M; Alviano F; Bonsi L; Nanni P; Lollini PL; Campadelli-Fiume G
Oncotarget; 2015 Oct; 6(33):34774-87. PubMed ID: 26430966
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel, high-efficacy oncolytic herpes simplex virus type 1 platform equipped with two distinct retargeting modalities.
Joo HY; Baek H; Ahn CS; Park ER; Lee Y; Lee S; Han M; Kim B; Jang YH; Kwon H
Mol Ther Oncol; 2024 Mar; 32(1):200778. PubMed ID: 38596302
[TBL] [Abstract][Full Text] [Related]
15. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.
Menotti L; Cerretani A; Hengel H; Campadelli-Fiume G
J Virol; 2008 Oct; 82(20):10153-61. PubMed ID: 18684832
[TBL] [Abstract][Full Text] [Related]
16. Retargeting Strategies for Oncolytic Herpes Simplex Viruses.
Campadelli-Fiume G; Petrovic B; Leoni V; Gianni T; Avitabile E; Casiraghi C; Gatta V
Viruses; 2016 Feb; 8(3):63. PubMed ID: 26927159
[TBL] [Abstract][Full Text] [Related]
17. Folate-conjugated herpes simplex virus for retargeting to tumor cells.
Ye ZQ; Zou CL; Chen HB; Lv QY; Wu RQ; Gu DN
J Gene Med; 2020 Jul; 22(7):e3177. PubMed ID: 32096291
[TBL] [Abstract][Full Text] [Related]
18. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
19. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
20. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.
Grandi P; Fernandez J; Szentirmai O; Carter R; Gianni D; Sena-Esteves M; Breakefield XO
Cancer Gene Ther; 2010 Sep; 17(9):655-63. PubMed ID: 20508670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
